Drug Profile
Research programme: vascular diseases - CollaGenex/Medtronic
Latest Information Update: 19 Apr 2010
Price :
$50
*
At a glance
- Originator CollaGenex Pharmaceuticals
- Developer CollaGenex Pharmaceuticals; Medtronic
- Class Tetracyclines
- Mechanism of Action Cytokine inhibitors; Peptide hydrolase inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
Highest Development Phases
- Discontinued Vascular disorders
Most Recent Events
- 19 Apr 2010 Discontinued - Preclinical for Vascular disorders in USA (Implant)
- 11 Apr 2008 CollaGenex Pharmaceuticals has been acquired by Galderma
- 04 Feb 2008 Preclinical development is ongoing